COVID-19 and Radiological Progression of Multiple Sclerosis
Diagnostics · 16.05.2026 · 16 (10) · 1513
DOI: 10.3390/diagnostics16101513 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diagnostics, online erschienen am 16.05.2026. Verfasst von Hien Quang Nguyen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Montefiore Health System, Albert Einstein College of Medicine, New York, NY 10461, USA. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: SARS-CoV-2 infection may exacerbate neuroinflammation in patients with multiple sclerosis (MS) and thus accelerate MS progression. Previous studies have reported an increased risk of disability and lesion burden among those infected with SARS-CoV-2 while others reported no differences compared to COVID− controls. We aimed to determine whether COVID-19 is associated with accelerated radiological progression of MS.
Methods
This single-center, retrospective longitudinal study included patients with pre-existing relapsing-remitting MS. We identified 34 SARS-CoV-2–positive MS patients (COVID+) who had at least one brain MRI prior to, and one after, their first positive PCR test. These patients were matched 2:1 by index date to 67 SARS-CoV-2–negative MS patients (COVID−). Baseline demographics and comorbidities were comparable between groups. Two radiologists independently scored pre- and post-index MRIs for new or enlarging T2 lesions, T1 gadolinium-enhancing lesions, and parenchymal brain volume loss. Logistic regression analyses evaluated group differences, adjusting for demographic and clinical covariates.
Results
Across an average imaging interval of approximately two years, no significant differences were observed between COVID+ and COVID− patients in new lesions (8.8% vs. 9.0%), enlarging lesions (2.9% vs. 6.0%), T1-enhancing lesions (5.9% vs. 1.5%), or brain volume loss (35.3% vs. 47.8%; all p > 0.05).
Conclusions
There was no detectable association between SARS-CoV-2 infection and accelerated radiological progression in patients with MS over an average two-year follow-up. Longer-term investigations are warranted to clarify whether certain subgroups or more severe COVID-19 cases might be at heightened risk.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiology, Montefiore Health System, Albert Einstein College of Medicine, New York, NY 10461, USA.
ORCID-Profile: Hien Quang Nguyen, Roham Hadidchi, Shounak Nandi, Jimmy Sanchez, Sonya Henry, Jimmy S Lee, Tim Q Duong
Zitieren
APA
Nguyen, H. Q., Hadidchi, R., Eligulashvili, A., Nandi, S., Vichare, A., Patel, B., Sanchez, J., Bisulca, J., Henry, S., Lee, J. S., & Duong, T. Q. (2026). COVID-19 and Radiological Progression of Multiple Sclerosis. Diagnostics, 16(10), 1513. https://doi.org/10.3390/diagnostics16101513
Vancouver
Nguyen HQ, Hadidchi R, Eligulashvili A, Nandi S, Vichare A, Patel B, et al. COVID-19 and Radiological Progression of Multiple Sclerosis. Diagnostics. 2026;16(10):1513. doi:10.3390/diagnostics16101513
BibTeX
@article{Nguyen2026,
author = {Nguyen, Hien Quang and Hadidchi, Roham and Eligulashvili, Anna and Nandi, Shounak and Vichare, Aditi and Patel, Bhakti and Sanchez, Jimmy and Bisulca, Joseph and Henry, Sonya and Lee, Jimmy S and Duong, Tim Q},
title = {COVID-19 and Radiological Progression of Multiple Sclerosis},
journal = {Diagnostics},
year = {2026},
volume = {16},
number = {10},
pages = {1513},
doi = {10.3390/diagnostics16101513}
}
EUVIMED